ReviewNature cancer2023
Understanding the mechanisms and translational implications of the microbiome for cancer therapy innovation.
Review in Nature cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Decoding the microbiome-immune crosstalk in cancer: from mechanisms to therapeutic translation.Biomarker research · 2026Review
- Analysis of intratumoural bacteria: Opportunities and challenges for cancer therapy.Acta pharmaceutica Sinica. B · 2026Review
- The emerging role of non-Gastroenterology report · 2026Review
- Advances in the engineering of living probiotics for cancer immunotherapy.Theranostics · 2026Review
- Article
- Microbiome-driven resistance in cervical cancer therapy: from mechanistic dissection to clinical translation.Expert reviews in molecular medicine · 2025Review
- Survival implications of the age-associated tumor and normal adjacent tissue microbiome among colorectal cancer patients.Gut pathogens · 2025Article
- Gut microbial metabolites in cancer immunomodulation.Molecular cancer · 2025Review
- Association Between Cholecystectomy and Gastric Cancer in a Cohort Study in Taiwan.Annals of gastroenterological surgery · 2025Article
- The microbiome in cancer.iMeta · 2025Review
- Molecular Mechanisms of Probiotic Action Against Gastrointestinal Cancers.International journal of molecular sciences · 2025Review
- Genetic evidence for causal links between diet, gut microbiota, and hepatobiliary cancer: a Mendelian randomization study.AMB Express · 2025Article
- Gut-Vaginal Microbiome Crosstalk in Ovarian Cancer: Implications for Early Diagnosis.Pathogens (Basel, Switzerland) · 2025Review
- HMGA1 acts as an epigenetic gatekeeper of ASCL2 and Wnt signaling during colon tumorigenesis.The Journal of clinical investigation · 2025Article
- Locally producing antibacterial peptide to deplete intratumoral pathogen for preventing metastatic breast cancer.Acta pharmaceutica Sinica. B · 2025Article
- Emerging technologies and current challenges in intratumoral microbiota research.Frontiers in cellular and infection microbiology · 2025Review
- When the microbiome meets One Health principle: Leading to the Holy Grail of biology and contributing to overall well-being and social sustainability.iMetaOmics · 2024Review
- Fecal microbial transplants as investigative tools in cancer.American journal of physiology. Gastrointestinal and liver physiology · 2024Review
- EPA, DHA, and resolvin effects on cancer risk: The underexplored mechanisms.Prostaglandins & other lipid mediators · 2024Review
- Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets.Signal transduction and targeted therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The intersection of the microbiota and cancer and the mechanisms that define these interactions are a fascinating, rapidly evolving area of cancer biology and therapeutics. Here we present recent insights into the mechanisms by which specific bacteria or their communities contribute to carcinogenesis and discuss the bidirectional interplay between microbiota and host gene or epigenome signaling. We conclude with comments on manipulation of the microbiota for the therapeutic benefit of patients with cancer.
Indexed as
Identifiers
37525016What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.